ClinicalTrials.gg
TerminatedNCT04903197Updated Apr 1, 2026

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

A Phase 1 interventional study of VAY736 and lenalidomide in Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, sponsored by Novartis Pharmaceuticals. Terminated at 10 sites in 7 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Why this study was terminated
Business decision and not due to any safety or tolerability concerns.

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Lymphoma, Non-Hodgkin by Novartis — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma, Non-Hodgkin · Novartis.

Enrollment
15th of 19
18 · median 37
Started
2022
with 1 other
Phase 1
9 of 19
none open now
Registered
18th of 19
by date

Among the 19 studies in Lymphoma, Non-Hodgkin by Novartis, this one is the 15th largest by enrollment, is one of 2 that started in 2022, is one of 9 in phase 1, and was the 18th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

1 of the 19 studies in Lymphoma, Non-Hodgkin by Novartis is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Lymphoma, Non-Hodgkin by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of VAY736 alone or in combination with other therapies in patients with NHL in a platform trial.

Read the detailed description

The primary objective of the study is to evaluate the safety and tolerability in patients with NHL and identify a maximum tolerated dose (MTD) and/or recommended dose (RD) of VAY736 single agent and in combination with other anti-cancer therapies.

This is a phase I/Ib, multi-center, open-label study with multiple treatment arms in an adaptive study design. The study is comprised of a dose escalation part and dose expansion part.

In dose escalation, the investigational drug VAY736 was explored alone or in combination with lenalidomide. Increasing doses of VAY736 alone or in combination were given to small groups of patients to identify the maximum tolerated dose/recommended dose (MTD/RD) in patients with NHL. In dose expansion, some or all the treatments from dose escalation could be tested at the recommended doses in patients with NHL. The study was expected to last approximately 4 years (from the enrollment of the first patient to the discontinuation of the last patient), but it was terminated early due to a business decision, not because of any safety or tolerability concerns. Consequently, the dose expansion part was not conducted.

03

Conditions studied

  • Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Keywords

  • VAY736
  • ianalumab
  • lenalidomide
  • non-Hodgkin lymphoma
  • NHL
  • Diffuse large B cell lymphoma
  • DLBCL
  • Follicular lymphoma
  • FL
  • Mantle cell lymphoma
  • MCL
  • Marginal zone lymphoma
  • MZL
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with confirmed diagnosis of B-cell NHL with all subtypes of DLBCL, follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) per WHO 2016 criteria. Patients in subtype arm e.g. DLBCL must have confirmed diagnosis of relapsed/refractory DLBCL.
  • Received and failed or be intolerant to standard of care therapy (at least two prior lines, including an anti-CD20 therapy for NHL)
  • Must have and of 0 to 2

Exclusion criteria

Exclusion Criteria:

  • Baseline laboratory results outside of protocol defined ranges
  • Patients with primary CNS lymphoma
  • History of to VAY736 or any drugs in similar chemical classes (e.g. monoclonal antibodies)
  • Impaired cardiac function or cardiac disease
  • History of or current interstitial lung disease or pneumonitis grade 2 or higher
  • infection
  • Active infection and/or infection
  • Pregnant or nursing (lactating) women
  • Women of unless they are using highly effective methods of

Other Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Arm 1A

    VAY736 single agent dose escalation in patients with NHL subtypes of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL)

    Drug: VAY736

  • Experimental
    Arm 1B

    VAY736 single agent dose expansion in patients with DLBCL. This arm was not conducted.

    Drug: VAY736

  • Experimental
    Arm 2A

    VAY736 + lenalidomide dose escalation in patients with DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL).

    Drug: VAY736 · Drug: lenalidomide

  • Experimental
    Arm 2B

    VAY736 + lenalidomide dose expansion in patients with DLBCL. This arm was not conducted.

    Drug: VAY736 · Drug: lenalidomide

Interventions

  • DrugVAY736

    VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.

    Also known as: ianalumab

  • Immune-modulatory agent that enhances activation of NK cells.

06

What researchers measure

Primary outcomes

  1. Incidence and nature of dose limiting toxicities (DLTs)

    Safety and tolerability

    Time frame: 28 days (first cycle of treatment)

  2. Incidence of Adverse events (AEs) and serious adverse events (SAEs)

    Incidence of AEs and SAEs is defined as number of participants with AEs and SAEs, including changes from baseline in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.

    Time frame: 4 years

  3. Number of patients with dose interruptions and dose reductions

    Safety and tolerability

    Time frame: 4 years

  4. Dose intensity

    Safety and tolerability

    Time frame: 4 years

Secondary outcomes

  1. Overall response rate (ORR)

    Efficacy will be assessed by Lugano Classification (FDG-PET/CT scans)

    Time frame: 4 years

  2. Best overall response (BOR) rate

    Efficacy will be assessed by Lugano Classification (FDG-PET/CT scans)

    Time frame: 4 years

  3. Area under curve (AUC) for VAY736 and combination partners

    PK parameters will be derived from serum concentrations

    Time frame: 4 years

  4. Maximum observed drug concentration after single dose administration (Cmax) for VAY736 and combination partners

    PK parameters will be derived from serum concentrations

    Time frame: 4 years

  5. Change from baseline in anti-drug antibodies (ADA)

    Blood samples will be collected to detect change in levels of antibodies to VAY736

    Time frame: Baseline, 4 years

07

Study locations

10 sites
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
  • Novartis Investigative Site
    Shanghai, 200032, China
  • Novartis Investigative Site
    Tianjin, 300020, China
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Yamagata, Yamagata 990 9585, Japan
  • Novartis Investigative Site
    Singapore, 119228, Singapore
  • Novartis Investigative Site
    Seoul, 03080, South Korea
  • Novartis Investigative Site
    Seoul, 05505, South Korea
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Feb 2025, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2021
First posted
May 26, 2021
StartActual
Jan 24, 2022
Primary completionActual
Feb 24, 2025
CompletionActual
Feb 24, 2025
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04903197
Responsible party
Sponsor
First posted
May 26, 2021
Start date
Jan 24, 2022
Primary completion
Feb 24, 2025
Completion
Feb 24, 2025
Last update
Apr 1, 2026

Study contacts

Novartis Institutes of Biomedical Research
study director · Novartis Institutes of Biomedical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion